Exome Sequencing in BRCA1-2 Candidate Familias: The Contribution of Other Cancer Susceptibility Genes

Hereditary Breast and Ovarian Cancer (HBOC) syndrome is a condition in which the risk of breast and ovarian cancer is higher than in the general population. The prevalent pathogenesis is attributable to inactivating variants of the BRCA1-2 highly penetrant genes, however, other cancer susceptibility genes may also be involved. By Whole Exome Sequencing (WES) we analyzed a series of 200 individuals selected for genetic testing in BRCA1-2 genes according to the updated National Comprehensive Cancer Network (NCCN) guidelines. Analysis by MLPA was performed to detect large BRCA1-2 deletions/duplications. Focusing on BRCA1-2 genes, data analysis identified 11 cases with pathogenic variants (4 in BRCA1 and 7 in BRCA1-2) and 12 with uncertain variants (7 in BRCA1 and 5 in BRCA2). Only one case was found with a large BRCA1 deletion. Whole exome analysis allowed to characterize pathogenic variants in 21 additional genes: 10 genes more traditionally associated to breast and ovarian cancer (ATM, BRIP1, CDH1, PALB2, PTEN, RAD51C, and TP53) (5% diagnostic yield) and 11 in candidate cancer susceptibility genes (DPYD, ERBB3, ERCC2, MUTYH, NQO2, NTHL1, PARK2, RAD54L, and RNASEL). In conclusion, this study allowed a personalized risk assessment and clinical surveillance in an increased number of HBOC families and to broaden the spectrum of causative variants also to candidate “non-canonical” genes.

• Publication year

  2021

• Venue

  Frontiers in Oncology

• Publication date

  2021-05-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2021.649435PMID 34026625PMCID 8139251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

  2020cited by this paper
• Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients

  2020cited by this paper
• NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

  2020cited by this paper
• Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer

  2019cited by this paper
• ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• Human Mutation

  2019cited by this paper
• PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

  2019cited by this paper
• Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients

  2019cited by this paper
• Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA‐negative Hispanics with breast cancer

  2019cited by this paper
• NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas

  2019cited by this paper
• Functional Classification of TP53 Mutations in Acute Myeloid Leukemia

  2019cited by this paper
• Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.

  2019cited by this paper
• The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries

  2019cited by this paper
• Identifying a BRCA2 c.5722_5723del mutation in a Han-Chinese family with breast cancer

  2019cited by this paper
• Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes

  2019cited by this paper
• The germline mutational landscape of BRCA1 and BRCA2 in Brazil

  2018cited by this paper
• Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.

  2018cited by this paper
• A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.

  2018cited by this paper
• Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

  2018cited by this paper
• Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy

  2018cited by this paper
• Variable population prevalence estimates of germline TP53 variants: A gnomAD‐based analysis

  2018cited by this paper
• Scaling accurate genetic variant discovery to tens of thousands of samples

  2017cited by this paper
• A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes

  2017cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• Outcomes of retesting BRCA negative patients using multigene panels

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer

  2017cited by this paper
• Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2

  2017cited by this paper
• Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer

  2016cited by this paper
• Penetrance of ATM Gene Mutations in Breast Cancer: A Meta‐Analysis of Different Measures of Risk

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia

  2016cited by this paper
• Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH

  2016cited by this paper
• Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

  2016cited by this paper
• Genomic Characterization of Primary Invasive Lobular Breast Cancer.

  2016cited by this paper
• Hereditary breast and ovarian cancer: new genes in confined pathways

  2016cited by this paper
• Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity

  2016cited by this paper
• Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

  2015cited by this paper
• Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.

  2015cited by this paper
• Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing

  2015cited by this paper
• Breast-cancer risk in families with mutations in PALB2.

  2014cited by this paper
• Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

  2014cited by this paper
• Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients

  2014cited by this paper
• Urinary diversion during and after pediatric pyeloplasty: a population based analysis of more than 2,000 patients.

  2014cited by this paper
• MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH‐Associated Polyposis

  2013cited by this paper
• MUTYH the base excision repair gene family member associated with colorectal cancer polyposis

  2013cited by this paper
• MUTYH the base excision repair gene family member associated with polyposis colorectal cancer

  2013cited by this paper
• MUTYH-associated polyposis (MAP), the syndrome implicating base excision repair in inherited predisposition to colorectal tumors

  2012cited by this paper
• Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

  2011cited by this paper
• Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility

  2011cited by this paper
• Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

  2011cited by this paper
• Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control

  2010cited by this paper
• Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies

  2010cited by this paper
• Founder BRCA 1 / 2 mutations in the Europe : implications for hereditary breast-ovarian cancer prevention and control

  2010cited by this paper
• Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer

  2010cited by this paper
• RAD51C germline mutations in breast and ovarian cancer patients

  2010cited by this paper
• Fast and accurate long-read alignment with Burrows–Wheeler transform

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53.

  2009cited by this paper
• The ERBB3 receptor in cancer and cancer gene therapy

  2008cited by this paper
• Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer‐prone xeroderma pigmentosum vs. non‐cancer‐prone trichothiodystrophy

  2008cited by this paper
• Meta-analysis of BRCA1 and BRCA2 penetrance.

  2007cited by this paper
• American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography

  2007cited by this paper
• Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

  2006cited by this paper
• Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

  2005cited by this paper
• Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

  2004cited by this paper
• Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

  2004cited by this paper
• Alterations of the Tumor Suppressor Gene Parkin in Non-Small Cell Lung Cancer

  2004cited by this paper
• Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27

  2003cited by this paper
• Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

  2003cited by this paper
• Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation

  2003cited by this paper
• Targeted Deletion of mNth1 Reveals a Novel DNA Repair Enzyme Activity

  2002cited by this paper
• Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.

  2002cited by this paper
• BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.

  2001cited by this paper
• Caspase-Dependent Apoptosis by 2′,5′-Oligoadenylate Activation of RNase L Is Enhanced by IFN-β

  2000cited by this paper
• Will the real Cowden syndrome please stand up: revised diagnostic criteria

  2000cited by this paper
• Mutations in the RAD54 recombination gene in primary cancers

  1999cited by this paper
• Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

  1998cited by this paper
• Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.

  1997cited by this paper
• Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

  1996cited by this paper
• E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.

  1995cited by this paper
• Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D.

  1995cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• A dominant negative mutant of 2‐5A‐dependent RNase suppresses antiproliferative and antiviral effects of interferon.

  1993cited by this paper
• Linkage of early-onset familial breast cancer to chromosome 17q21.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.

  1988cited by this paper

• The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers

  2026cites this paper
• Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment

  2025cites this paper
• The role of genetics and epigenetics in breast cancer: A comprehensive review of metastasis, risk factors, and future perspectives

  2025cites this paper
• Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future

  2024influential citation
• Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

  2023cites this paper
• Genetic and molecular analyses of candidate germline BRIP1/FANCJ variants implicated in breast and ovarian cancer

  2023cites this paper
• Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.

  2023cites this paper
• Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

  2023cites this paper
• The Identification by Exome Sequencing of Candidate Genes in BRCA-Negative Tunisian Patients at a High Risk of Hereditary Breast/Ovarian Cancer

  2022cites this paper
• Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment

  2022cites this paper
• Intestinal and extraintestinal neoplasms in patients with NTHL1 tumor syndrome: a systematic review

  2022cites this paper
• Multi-gene panel testing increases germline predisposing mutations’ detection in a cohort of breast/ovarian cancer patients from Southern Italy

  2022cites this paper
• Coupled MD simulations and NMR reveal that the intrinsically disordered domain of the breast-cancer susceptibility 1 protein (BRCA1) binds head-on to DNA double-strand ends

  2022cites this paper
• Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family.

  2022cites this paper
• Effect of Rho GTPase activating protein 9 combined with preoperative ratio of platelet distribution width to platelet count on prognosis of patients with serous ovarian cancer

  2021cites this paper